Vaxcyte, Inc.
Clinical trials sponsored by Vaxcyte, Inc., explained in plain language.
-
New 31-Strain pneumonia vaccine shows promise in large trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 to see if it is safe and creates a strong immune response against pneumonia-causing bacteria. About 4,000 healthy adults aged 50 and older, plus some younger adults, will receive either VAX-31 or an existing vaccine. Researchers will c…
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 12:54 UTC
-
New baby vaccine aims to beat pneumonia
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called VAX-31 to protect babies against pneumococcal disease, which can cause pneumonia and meningitis. About 905 healthy infants will receive four doses of VAX-31 or a current vaccine at 2, 4, 6, and 12-15 months old. Researchers will check for sid…
Phase: PHASE2 • Sponsor: Vaxcyte, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 08, 2026 12:03 UTC
-
New combo shot study: could one visit protect against 31 pneumonia strains and flu?
Prevention OngoingThis study tests a new vaccine called VAX-31, which targets 31 types of bacteria that cause pneumonia and other infections. Researchers want to see if it is safe and works well when given at the same time as the seasonal flu shot in healthy adults aged 50 and older. About 1,390 p…
Phase: PHASE3 • Sponsor: Vaxcyte, Inc. • Aim: Prevention
Last updated May 07, 2026 18:41 UTC